Latest Inhaler Stories

WALTHAM, Mass., Feb. 2 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Boehringer Ingelheim/Pfizer's Spiriva will retain Decision Resources' proprietary clinical gold standard status for the treatment of chronic obstructive pulmonary disease (COPD) through 2018. While some drugs in development for COPD hold promise, most have less favorable efficacy, safety and tolerability, and/or delivery...

LOURES, Portugal, February 2 /PRNewswire/ -- Hovione is announcing the filing of a new drug application in Japan by its licensee Daiichi Sankyo Company Ltd. for the influenza drug CS-8958, which is delivered using Hovione's TwinCaps(R) inhaler. Being pre-filled, disposable and low-cost, TwinCaps(R) was specifically developed for the influenza indication and may thus be used for inhaled drug delivery to the lung in other acute indications, such as bacterial or viral infections....

REDWOOD CITY, Calif., Feb. 1 /PRNewswire/ -- Pearl Therapeutics Inc., a company developing clinically differentiated combination therapies for the treatment of highly prevalent chronic respiratory diseases, including chronic obstructive pulmonary disease (COPD), today announced a $15 million financing from existing investors Clarus Ventures, New Leaf Venture Partners and 5AM Ventures. The capital was raised through a convertible loan facility that will convert to Pearl equity at the time of...

HORSHAM, Pa., Jan. 26 /PRNewswire/ -- While cold and flu season is always unpredictable, this year is already one of the worst to date with flu outbreaks across the nation stemming from the arrival of the H1N1 virus and another wave of seasonal flu on the horizon. People with asthma or chronic obstructive pulmonary disease (COPD) are at higher risk of developing severe respiratory symptoms if they contract a cold or the flu, and those with asthma account for about one-third of all people...

SAN DIEGO, Jan. 21 /PRNewswire/ -- Elevation Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of new aerosol therapies for patients with respiratory diseases, announced today the closing of a $30 million tranched Series A financing. Investors participating include Canaan Partners, TPG Growth, Care Capital, and Mesa Verde Venture Partners. Concurrent with this financing, Elevation has added to its board of directors Brent Ahrens, General Partner at Canaan,...

REDWOOD CITY, Calif., Jan. 6 /PRNewswire/ -- Pearl Therapeutics Inc., a company developing high-quality combination therapies for the treatment of highly prevalent chronic respiratory diseases, today announced positive results from a Phase 2a dose-ranging study of PT001, the company's glycopyrrolate hydrofluoroalkane metered dose inhaler (HFA-MDI) formulation. The data showed that PT001 was well tolerated and was comparable in bronchodilator efficacy and safety to the active control drug...

Findings show that air pollution is effecting the rescue inhalers people use for quick relief of asthma, according to a recent Reuters report.A study was done on 85 asthmatic children living in Mexico City, ages 7 to 12, to see whether outdoor air pollution had any impact on how well their rescue inhalers worked. Traffic pollution is usually very high in this area.Fifty-three of the children had mild intermittent asthma, 20 had mild persistent asthma, and 12 had moderate persistent asthma.Dr....

HORSHAM, Pa., Dec. 7 /PRNewswire-FirstCall/ -- Teva Respiratory, a division of Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA), today announced the publication of four articles in a special supplement of the December issue of the Journal of Allergy and Clinical Immunology (JACI), providing a comprehensive scientific review of the emerging role of the small airways in the understanding and treatment of asthma. This represents the first time leading researchers from various institutions in...

NEW YORK, Dec. 2 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Global Markets for Asthma and COPD Drugs http://www.reportlinker.com/p0166826/Global-Markets-for-Asthma-and-COPD-Drugs.html Provides an in-depth analysis of the global market for medications that treat asthma and chronic obstructive pulmonary disease Contains global market forecasts through 2014 for medications that treat asthma and chronic obstructive pulmonary...

NEW YORK, Nov. 18 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Pulmonary Drug Delivery Technologies - A Global Market Perspective http://www.reportlinker.com/p0164238/Pulmonary-Drug-Delivery-Technologies---A-Global-Market-Perspective.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire Until recent years, respiratory conditions such as asthma, chronic obstructive pulmonary, and emphysema disease represented...